FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013145504> ?p ?o ?g. }

• W2013145504 endingPage "295" @default.
• W2013145504 startingPage "291" @default.
• W2013145504 abstract "To determine the frequency of anti-cardiolipin (aCL) and anti-β2-glycoprotein I antibodies (aβ2GPI) in celiac disease (CD) patients. Sixty-three untreated CD patients and 40 healthy blood donors (HBD) were studied. IgG, IgA and IgM aCL and aβ2GPI were detected by Elisa. The frequency of antiphospholipid antibodies (aPL) (aCL and/or aβ2GPI) was significantly higher in CD patients (12 out of 63) than in HBD (two out of 40) (19% vs 5%, P = 0.04). Six CD patients out of 63 (9.5%) and one HBD out of 40 (2.5%) had aCL. Ten CD patients (15.9%) and two HBD (5%) had aβ2GPI. Only aβ2GPI-IgA was significantly more frequent in CD patients than in HBD (14.3% vs 2.5%, P = 0.048). In CD patients, aβ2GPI-IgA (nine out of 63) was significantly more frequent (14.3%) than aβ2GPI-IgG (1.6%) and IgM (1.6%) (P = 0.008). In CD patients, the frequency of aCL-IgA and IgM was 6.3% (four out of 63) and aCL-IgG were not detected. Simultaneous presence of positive antibodies was found in four CD patients: one patient had four aPL, one had three aPL and two had two aPL. The four patients who had aCL-IgA had also aβ2GPI-IgA and three of them had a titer higher than 50 units. Among nine patients with aβ2GPI-IgA, four had a titer higher than 100 units. The highest titers were found in adults. aPL and particularly aβ2GPI-IgA are frequent in CD. The significance of these antibodies has to be determined. Déterminer la fréquence des anticorps anti-cardiolipine (aCL) et anti-β2 glycoprotéine I (aβ2GPI) au cours de la maladie cœliaque (MC). Notre étude rétrospective a été réalisée sur 63 patients cœliaques non traités. Quarante donneurs de sang ont servi comme témoins. Les aCL et les aβ2GPI d’isotype IgG, IgA et IgM ont été recherchés par la technique Elisa. La fréquence des anticorps antiphospholipides (aPL) (aCL et/ou aβ2GPI) est significativement plus élevée chez les patients cœliaques (12 sur 63) que chez les sujets sains (deux sur 40) (19 % vs 5 %, p = 0,04). Six patients parmi 63 (9,5 %) et un sujet sain parmi 40 (2,5 %) ont les aCL. Dix patients (15,9 %) et deux témoins (5 %) ont les aβ2GPI. Seuls les aβ2GPI-IgA sont significativement plus fréquents chez les patients cœliaques que chez les donneurs de sang (14,3 % vs 2,5 %, p = 0,048). Chez les patients cœliaques, les aβ2GPI-IgA (neuf sur 63) sont significativement plus fréquents (14,3 %) que les aβ2GPI-IgG (1,6 %) et les aβ2GPI-IgM (1,6 %) (p = 0,008). Chez les patients cœliaques, la fréquence des aCL-IgA et IgM est de 6,3 % (quatre sur 63) alors que les aCL-IgG ne sont pas détectés. La présence simultanée des aPL a été observée chez quatre patients : un patient a quatre aPL, un a trois aPL et deux ont deux aPL. Les quatre patients qui ont les aCL-IgA ont aussi les aβ2GPI-IgA et trois parmi eux ont un titre supérieur à 50 unités. Parmi les neuf patients ayant les aβ2GPI-IgA, quatre ont un titre supérieur à 100 unités. Les titres les plus élevés ont été retrouvés chez les adultes. Les aPL et en particulier les aβ2GPI-IgA sont fréquents au cours de la MC. La signification de ces anticorps reste à déterminer." @default.
• W2013145504 created "2016-06-24" @default.
• W2013145504 creator A5004966797 @default.
• W2013145504 creator A5014923012 @default.
• W2013145504 creator A5021819902 @default.
• W2013145504 creator A5033851795 @default.
• W2013145504 creator A5060920288 @default.
• W2013145504 creator A5062977434 @default.
• W2013145504 date "2012-10-01" @default.
• W2013145504 modified "2023-10-14" @default.
• W2013145504 title "Anti-cardiolipin and anti-beta 2-glycoprotein I antibodies in celiac disease" @default.
• W2013145504 cites W1508188343 @default.
• W2013145504 cites W1973609549 @default.
• W2013145504 cites W1982797020 @default.
• W2013145504 cites W1983687448 @default.
• W2013145504 cites W1986348058 @default.
• W2013145504 cites W1987433373 @default.
• W2013145504 cites W2002859744 @default.
• W2013145504 cites W2020578138 @default.
• W2013145504 cites W2029471701 @default.
• W2013145504 cites W2032162517 @default.
• W2013145504 cites W2042189284 @default.
• W2013145504 cites W2043568401 @default.
• W2013145504 cites W2064702948 @default.
• W2013145504 cites W2077623799 @default.
• W2013145504 cites W2082106921 @default.
• W2013145504 cites W2086801282 @default.
• W2013145504 cites W2102162665 @default.
• W2013145504 cites W2102727554 @default.
• W2013145504 cites W2106642319 @default.
• W2013145504 cites W2110803155 @default.
• W2013145504 cites W2120545107 @default.
• W2013145504 cites W2135711030 @default.
• W2013145504 cites W2136320214 @default.
• W2013145504 cites W2139013251 @default.
• W2013145504 cites W2164810820 @default.
• W2013145504 cites W2328593223 @default.
• W2013145504 cites W4245464873 @default.
• W2013145504 doi "https://doi.org/10.1016/j.patbio.2011.07.003" @default.
• W2013145504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21839587" @default.
• W2013145504 hasPublicationYear "2012" @default.
• W2013145504 type Work @default.
• W2013145504 sameAs 2013145504 @default.
• W2013145504 citedByCount "16" @default.
• W2013145504 countsByYear W20131455042013 @default.
• W2013145504 countsByYear W20131455042014 @default.
• W2013145504 countsByYear W20131455042015 @default.
• W2013145504 countsByYear W20131455042016 @default.
• W2013145504 countsByYear W20131455042017 @default.
• W2013145504 countsByYear W20131455042018 @default.
• W2013145504 countsByYear W20131455042020 @default.
• W2013145504 countsByYear W20131455042022 @default.
• W2013145504 crossrefType "journal-article" @default.
• W2013145504 hasAuthorship W2013145504A5004966797 @default.
• W2013145504 hasAuthorship W2013145504A5014923012 @default.
• W2013145504 hasAuthorship W2013145504A5021819902 @default.
• W2013145504 hasAuthorship W2013145504A5033851795 @default.
• W2013145504 hasAuthorship W2013145504A5060920288 @default.
• W2013145504 hasAuthorship W2013145504A5062977434 @default.
• W2013145504 hasConcept C126322002 @default.
• W2013145504 hasConcept C159654299 @default.
• W2013145504 hasConcept C203014093 @default.
• W2013145504 hasConcept C2776874634 @default.
• W2013145504 hasConcept C2779102806 @default.
• W2013145504 hasConcept C2779134260 @default.
• W2013145504 hasConcept C2780349322 @default.
• W2013145504 hasConcept C2780898057 @default.
• W2013145504 hasConcept C32611913 @default.
• W2013145504 hasConcept C71924100 @default.
• W2013145504 hasConcept C90924648 @default.
• W2013145504 hasConceptScore W2013145504C126322002 @default.
• W2013145504 hasConceptScore W2013145504C159654299 @default.
• W2013145504 hasConceptScore W2013145504C203014093 @default.
• W2013145504 hasConceptScore W2013145504C2776874634 @default.
• W2013145504 hasConceptScore W2013145504C2779102806 @default.
• W2013145504 hasConceptScore W2013145504C2779134260 @default.
• W2013145504 hasConceptScore W2013145504C2780349322 @default.
• W2013145504 hasConceptScore W2013145504C2780898057 @default.
• W2013145504 hasConceptScore W2013145504C32611913 @default.
• W2013145504 hasConceptScore W2013145504C71924100 @default.
• W2013145504 hasConceptScore W2013145504C90924648 @default.
• W2013145504 hasIssue "5" @default.
• W2013145504 hasLocation W20131455041 @default.
• W2013145504 hasLocation W20131455042 @default.
• W2013145504 hasOpenAccess W2013145504 @default.
• W2013145504 hasPrimaryLocation W20131455041 @default.
• W2013145504 hasRelatedWork W172778746 @default.
• W2013145504 hasRelatedWork W1996563985 @default.
• W2013145504 hasRelatedWork W2029699778 @default.
• W2013145504 hasRelatedWork W2057336173 @default.
• W2013145504 hasRelatedWork W2078748389 @default.
• W2013145504 hasRelatedWork W2144285235 @default.
• W2013145504 hasRelatedWork W2145781638 @default.
• W2013145504 hasRelatedWork W2401779655 @default.
• W2013145504 hasRelatedWork W2491537557 @default.
• W2013145504 hasRelatedWork W4244345790 @default.
• W2013145504 hasVolume "60" @default.
• W2013145504 isParatext "false" @default.

• next